• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models – Science Translational Medicine

Aug 7, 2024 | Publications

Click here to view...

A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation

Jul 24, 2023 | Publications

Click here to view...

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned – PLOS Pathogens

Apr 19, 2023 | Publications

Click here to view...

Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model – Molecular Therapy

Mar 24, 2023 | Publications

Click here to view...

Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen — Tuberculosis

Feb 1, 2023 | Publications

Click here to view...

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis – Vaccines 2023

Feb 1, 2023 | Publications

Click here to view...
« Older Entries

Recent Posts

  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
  • Institutional Biosafety Committee
  • MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
  • Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow